Chat with us, powered by LiveChat
Main Number 646-604-2821 info@curtiscoulter.com

Big Picture Outlook

According to markets & Markets, the drug delivery technology market is expected to reach USD $1,669.4 Billion by 2020 from USD $1,179.2 Billion in 2016, growing at a CAGR of 7.2% during the forecast period. Geographically, Asia is projected to grow the most during this period. Regarding routes of administration, the market is predominantly segmented into oral, injectable, topical, nasal, ocular, pulmonary, implantable, and transmucosa. From 3-D printing, to non-oral delivery of biologics, to advances in nanotechnology, the future for drug delivery is ripe with innovation, but what is likely primed for market success?

With the increasing prevalence of chronic diseases, as well as demand for biologics (notably peptides), technological advancements, and new product launches, these are some of the main factors driving growth in the drug delivery technology market. Additionally, self-administration & home care and an increased demand for biosimilars and generic drugs offer significant growth opportunities for drug delivery manufacturers.

In a nutshell, there will be a significant growth in both commercial delivery technologies and whacky novel approaches flooding the market over the next few years.

Starting from Scratch Worth it?

Developing a new drug that receives market approval can cost $2.6 billion, according to the Tufts Center for the Study of Drug Development. Given the high costs involved in the drug development process, formulating products that improve delivery has clear cost implications for the industry as well the patient experience. Certain factors play a part – bioavailability, drug release profile and effectiveness. Is the product for self-administration, likely to be for emergency use? Is it for a child or someone with swallowing issues such as the elderly? Does it need to be a slow release formula or take the form of suppositories? Addressing patient requirements can make the difference between a drug being taken correctly and not being taken at all, which may have adverse effects on the health of the patient.

Biologics Thriving?

Biologics are expanding rapidly (BCC Research states that the global market value for biologics is expected to reach $252 billion this year) especially within the peptide and protein areas. Commercial scale-up manufacturing continues to pose a problem due to the complexities of the products however the delivery market opportunities are plentiful. There are some exciting developments within oral delivery of peptides and proteins, which some consider the holy grail of drug delivery.

Size Doesn’t Matter?

The development of nanomedicines (including utilization of nanocrystals, nanoparticles, liposomes) has increased with conditions such as cancer, cardiovascular disease and obesity benefitting from the development of this form of drug delivery. There are also significant advances within targeted and localized delivery, opening up a new wave of products potential for drug manufacturers, not to mention developing modified release products.

Want to Learn More?

 

Consider joining us in Philadelphia, PA this August (27- 29th August, 2019) at the 2019 Controlled & Modified Drug Release Summit and learn 2 years worth of new product development strategies in just 3 days! This industry-leading event will bring together key decision makers and innovators within this rapidly growing space. By attending this unique event, you will learn directly from industry’s leading experts and hear unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.

Why Consider Attending the 2019 Controlled & Modified Drug Release Summit (CR6)?

  • 50+ industry-led speaker faculty over 2 full days sharing innovative drug development take-home strategies
  • 14+ hours of networking sessions and breaks over two full days to learn from network with pharmaceutical and biotech senior formulation, development and delivery professionals
  • 160+ Senior Participants spanning pharma, biotech and specialty delivery & technology companies
  • Dynamic Tech Showcase Hall with multiple leading formulation development, excipient suppliers, delivery and modeling experts
  • 2 Events in One! Co-located and shared tech showcase with the 2019 Peptide Drug Design & Delivery Summit

Benefit from industry participation from Pfizer, Merck, Novartis, Bristol Myers Squibb, GlaxoSmithKline, Celgene, Johnson & Johnson, and many more controlled and modified drug release innovators. Consider joining us in Philadelphia this August to enhance your drug delivery and formulation capabilities, which will decrease time to market on your drug products. Secure your seat TODAY!

WANT TO ATTEND CR6 BUT NEED HELP CONVINCING YOUR BOSS?

Let us help by generating you a custom message for you to send to your boss. Email it, talk them through it in person, tweet it to them 280 characters at a time: up to you.

We’re committed to your privacy. Curtis & Coulter uses the information you provide to us to contact you about upcoming and future events. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Pin It on Pinterest

Share This

Share this with a friend or colleague!